PCM
GYRE icon

Prelude Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Prelude Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-107
Closed -$5K – 1656
2019
Q4 		$5K Buy
+107
New +$4.48K ﹤0.01% 1773
2014
Q3 		– Sell
-1
Closed -$2.47K – 1955
2014
Q2 		$3K Buy
+1
New +$3.26K ﹤0.01% 1858

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Prelude Capital Management's GYRE Position: Q1 2020 in Review

Prelude Capital Management sold out of Gyre Therapeutics (GYRE) in Q1 2020, closing a stake of 107 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in GYRE in Q2 2014 and held it in 2 quarters. The position peaked at $5K in Q4 2019. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2020.

  • Prelude Capital Management reported no remaining Gyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 107 Gyre Therapeutics shares in Q1 2020, an estimated $5K.
  • Prelude Capital Management first reported a position in Gyre Therapeutics in Q2 2014 and held it in 2 quarters.
  • Prelude Capital Management's Gyre Therapeutics position peaked at $5K in Q4 2019.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.